coronaviru
diseas
global
pandem
rage
across
globe
race
prevent
treat
deadli
diseas
led
offlabel
repurpos
drug
hydroxychloroquin
lopinavirritonavir
potenti
unwant
qtinterv
prolong
risk
druginduc
sudden
cardiac
death
possibl
consider
inc
emerg
wuhan
provinc
china
late
sever
acut
respiratori
syndrom
coronaviru
viru
respons
coronaviru
diseas
respiratori
ill
alreadi
claim
live
individu
worldwid
number
case
death
increas
pass
day
perhap
press
need
medicin
identifi
safe
efficaci
therapi
prevent
infect
well
attenu
sever
result
respiratori
ill
although
us
food
drug
administr
fda
eapprov
drug
prevent
treat
number
promis
novel
ie
remdesivir
repurpos
ie
hydroxychloroquin
potenti
togeth
azithromycin
pharmacolog
agent
report
inhibit
growth
vitro
evalu
random
clinic
trial
advanc
definit
evid
clinician
front
line
pandem
begun
use
medic
offlabel
compassionateus
circumst
anecdot
success
light
need
practic
continu
absenc
viabl
evidencebas
therapi
procliv
mani
promis
pharmacotherapiesdspecif
antimalari
agent
hydroxychloroquinedto
prolong
qtc
therebi
increas
risk
druginduc
torsad
de
point
ditdp
drug
inducedsudden
cardiac
death
discd
document
assembl
help
health
care
profession
safe
use
medic
minim
concomit
risk
chloroquin
analogu
hydroxychloroquin
use
nearli
year
prophylact
pharmacotherapi
malaria
although
still
use
antimalari
agent
part
world
chloroquinesensit
plasmodium
falciparum
protozoa
hydroxychloroquin
found
new
life
diseasemodifi
antirheumat
drug
manag
condit
system
lupu
erythematosu
rheumatoid
arthriti
cellular
level
antimalari
drug
accumul
intracellular
vesicl
endosom
lysosom
proton
lead
increas
vesicular
ph
process
turn
inhibit
activ
phdepend
proteas
involv
intracellular
process
secretori
protein
number
immunolog
nonimmunolog
effect
includ
tumor
necrosi
factor
interleukin
collect
reduct
secretori
protein
believ
result
accumul
cytotox
heme
poison
p
falciparum
protozoa
modul
immun
cell
behavior
manner
attenu
inflammatori
process
addit
chloroquin
hydroxychloroquin
possess
antivir
properti
vitro
chloroquin
hydroxychloroquin
believ
act
entri
postentri
stage
sever
acut
respiratori
syndrom
coronaviru
infect
like
via
effect
endosom
ph
result
underglycosyl
angiotensinconvert
enzym
receptor
requir
viral
entri
base
vitro
data
hypothes
hydroxychloroquin
chloroquin
may
therapeut
efficaci
pandem
prevent
infect
inhibit
angiotensinconvert
enzym
viral
entri
ie
preinfect
prophylaxi
attenu
postvir
cytokin
storm
observ
sever
case
via
multitud
immunomodulatori
mechan
ie
treatment
activ
infectionpostvir
sequela
promis
vitro
data
well
anecdot
vivo
evid
therapeut
benefit
led
mani
institut
includ
mayo
clinic
consid
use
hydroxychloroquin
firstlin
pharmacotherapi
time
spur
array
clinic
trial
design
assess
efficaci
repurpos
hydroxychloroquin
prevent
treatment
although
collect
safeti
profil
chloroquin
hydroxychloroquin
rel
favor
drug
block
hergk
v
potassium
channel
potenti
prolong
qtc
atrisk
individu
socal
herg
blocker
precipit
ditdp
wors
discd
especi
longterm
use
tabl
result
number
discd
attribut
hydroxychloroquin
particular
trivial
tabl
theoret
possibl
substanti
proport
world
popul
could
receiv
hydroxychloroquin
firstlin
prophylaxi
treatment
includ
estim
million
individu
congenit
long
qt
syndrom
lqt
number
hydroxychloroquinemedi
discd
could
increas
precipit
unless
appropri
qtc
monitor
algorithm
institut
risk
discd
could
amplifi
multipl
medic
qtcprolong
torsadogen
potenti
ie
chloroquin
hydroxychloroquin
plu
azithromycin
lopinavirritonavir
use
combin
tabl
although
might
argu
discd
set
widespread
chloroquin
hydroxychloroquin
use
repres
accept
friendli
fire
war
believ
institut
simpl
safe
precaut
risk
ditdp
discd
mitig
ultim
come
identifi
small
subset
individu
either
secondari
underli
genet
predisposit
congenit
lqt
present
peopl
andor
virtu
presenc
multipl
modifi
nonmodifi
qtc
risk
factor
tabl
excess
baselin
qtc
prolong
qtc
ms
andor
inher
tendenc
develop
exagger
qtc
respons
ie
dqtc
ms
follow
exposur
medic
advers
effect
potenti
qtc
prolong
figur
although
percentag
individu
risk
small
given
pandem
natur
absolut
term
number
individu
potenti
risk
lethal
advers
drug
effect
larg
least
individu
patient
worldwid
expect
increas
risk
ditdp
discd
treat
medic
issu
would
especi
true
medic
adopt
postexposur
prophylaxi
tradit
qtc
calcul
either
lead
ii
v
electrocardiogram
ecg
correct
heart
rate
use
bazett
fridericia
formula
intraindividu
interindividu
qtc
comparison
made
unfortun
context
pandem
acquisit
patient
qtc
ecg
requir
addit
personnel
exposur
ie
ecg
technician
necess
serial
ecg
requir
exposur
complex
equip
multipl
ecg
wire
could
strain
alreadi
limit
suppli
person
protect
equip
ppe
mani
countri
altern
fdaapprov
consum
mobil
ecg
devic
capabl
gener
accur
qtc
measur
end
alivecor
inc
receiv
emerg
clearanc
fda
use
kardiamobil
devic
fdaapprov
atrial
fibril
detect
qtc
monitor
patient
treat
qtprolong
medic
chloroquinehydroxychloroquin
march
pm
cst
similarli
mani
telemetri
system
equip
realtim
qtc
monitor
featur
could
use
hospit
patient
patient
treat
medic
increas
potenti
ditdpdiscd
figur
baselin
qtc
statu
obtain
either
tradit
ecg
perhap
prefer
use
smartphoneen
mobil
qtc
meter
use
simpl
infect
control
measur
outlin
figur
limit
personnel
exposur
conserv
critic
ppe
averag
qtc
valu
otherwis
healthi
postpubert
male
femal
around
ms
ms
respect
contrast
qtc
valu
exce
percentil
valu
otherwis
healthi
individu
ie
ms
sex
puberti
ms
postpubert
male
ms
postpubert
femal
absenc
exogen
qtcaggrav
factor
may
signal
individu
increas
risk
qtrelat
ventricular
arrhythmia
contrast
frame
refer
averag
qtc
valu
ms
patient
congenit
lqt
care
mayo
clinic
windland
smith
rice
genet
heart
rhythm
clinic
furthermor
except
amiodaron
one
patient
rest
qtc
ms
whether
secondari
congenit
lqt
acquir
qtcprolong
drug
qtcprolong
electrolyt
abnorm
hypokalemia
qtcprolong
diseas
state
detail
tabl
consider
greater
risk
ditdp
discd
accordingli
baselin
qtc
valu
use
roughli
approxim
patient
risk
ditdpdiscd
follow
initi
medic
qtcprolong
potenti
patient
qtc
valu
less
percentil
agesex
ie
ms
prepubert
malesfemal
ms
postpubert
male
ms
postpubert
femal
figur
green
light
statu
risk
ditdpdilqt
low
chloroquinehydroxychloroquin
qtcprolong
pharmacotherapi
initi
without
delay
outlin
qtc
monitor
algorithm
rememb
whether
ecg
telemetri
smartphoneen
acquisit
ecg
note
qt
interv
less
onehalf
preced
rr
interv
calcul
qtc
alway
less
ms
patient
green
light
go
treatment
may
qtcprolong
potenti
contrast
patient
baselin
qtc
ms
greater
increas
risk
ditdpdiscd
figur
red
light
statu
everi
effort
made
assess
correct
contribut
electrolyt
abnorm
hypocalcemia
ye
ye
ye
correct
electrolyt
abnorm
k
mg
discontinu
unnecessari
q
tcprolong
medic
strict
isol
x
day
symptomat
manag
follow
insitutionalpubl
health
protocol
regard
checkinfollowup
time
age
immunosuppress
state
transplant
malign
uncontrol
hiv
activ
chemotherapyimmunotherapi
highrisk
comorbid
condit
ckd
copd
chf
cystic
fibrosi
pulmonari
fibrosi
obtain
pretreat
q
tc
use
standard
ecg
telemetri
mobil
ecg
devic
see
figur
detail
obtain
baselin
expand
electrolyt
ca
mg
k
determin
home
qtcprolong
medic
discontinu
wwwqtdrugsorg
document
highrisk
cv
comorbid
condit
see
tabl
qtc
ms
prepuberti
ms
postpubert
male
ms
postpubert
femal
ms
repeat
qtc
use
standard
ecg
telemetri
mobil
ecg
devic
see
figur
detail
obtain
baselin
expand
electrolyt
ca
mg
k
consid
altern
nonqtcprolong
therapi
vitro
activ
therapi
print
web
figur
approach
mitig
risk
druginduc
torsad
de
point
tdp
druginduc
sudden
cardiac
death
patient
coronaviru
diseas
treat
follow
hypothet
treatment
algorithm
offlabel
hydroxychloroquin
alon
combin
azithromycin
medic
known
herg
blocker
qtcprolong
torsadogen
potenti
estim
percentil
qtc
valu
deriv
otherwis
healthi
individu
place
patient
green
light
categori
less
ms
puberti
less
ms
men
less
ms
women
estim
baselin
qtc
assess
place
patient
green
light
yellow
light
red
light
statu
sever
case
defin
respiratori
rate
greater
breathsmin
adult
breathsmin
children
oxygen
satur
less
pao
fraction
inspir
oxygen
ratio
less
lung
infiltr
involv
lung
field
hour
hydroxychloroquin
inhibit
sever
acut
respiratori
syndrom
coronaviru
vitro
reduc
viral
burden
small
french
studi
random
control
trial
data
avail
support
clinic
efficaci
hydroxychloroquin
use
use
remain
label
present
u
repurpos
antivir
altern
lopinavirritonavir
also
qtcprolong
effect
bid
twice
daili
chf
congest
heart
failur
ckd
chronic
kidney
diseas
copd
chronic
obstruct
pulmonari
diseas
cv
cardiovascular
ecg
electrocardiographi
icu
intens
care
unit
iv
intraven
niaid
nation
institut
allergi
infecti
diseas
po
mouth
mayo
clin
proc
n
xxx
nn
n
n
http
wwwmayoclinicproceedingsorg
hypokalemia
andor
hypomagnesemia
review
discontinu
unnecessari
qtcprolong
medic
present
transit
altern
less
qtc
liabil
andor
proceed
closer
monitor
telemetri
even
consider
advanc
countermeasur
equip
patient
wearabl
defibril
eg
lifevest
zoll
medic
corpor
decis
made
commenc
therapi
set
qtc
valu
ms
greater
navig
circumv
qtc
liabil
depend
greatli
riskbenefit
calculu
decis
rest
treat
clinician
patient
exampl
younger
patient
ie
year
mild
symptom
qtc
ms
greater
may
reason
avoid
treatment
altogeth
arrhythmia
risk
may
outweigh
risk
develop
acut
respiratori
distress
syndrom
howev
patient
qtc
ms
greater
present
progress
worsen
respiratori
symptom
greater
risk
ie
year
age
immunosuppress
andor
highrisk
comorbid
condit
respiratori
complic
potenti
benefit
qtcprolong
pharmacotherapi
may
exceed
arrhythmia
risk
therefor
ultim
goal
qtc
surveil
pandem
identifi
receiv
medic
identifi
compromis
reduc
repolar
reserv
increas
qtc
countermeasur
taken
mitig
risk
drugrel
death
ditdpdiscd
ultim
much
riskbenefit
calculu
await
determin
therapeut
efficaci
hydroxychloroquin
without
concomit
azithromycin
inform
avail
decis
figur
protocol
possibl
inpati
outpati
use
smartphoneen
mobil
electrocardiogram
ecg
assess
monitor
qtc
valu
patient
coronaviru
diseas
inpati
protocol
use
dedic
institut
smartphon
tablet
mobil
ecg
devic
whenev
possibl
strongli
recommend
use
dedic
institut
bluetoothen
smartphon
tablet
devic
use
person
use
ie
phone
call
activ
limit
spread
sever
acut
respiratori
syndrom
coronaviru
b
inpati
outpati
protocol
use
person
institut
loan
smartphonetablet
mobil
ecg
devic
current
smartphoneen
mobil
ecg
us
food
drug
administr
approv
qtc
monitor
alivecor
kardiamobil
devic
ppe
person
protect
equip
made
treat
patient
red
light
design
figur
base
baselin
qtc
ms
greater
seem
prudent
start
hydroxychloroquin
alon
rather
combin
drug
therapi
azithromycin
addit
combin
drug
therapi
hydroxychloroquin
azithromycin
initi
patient
initi
green
lightyellow
light
qtc
statu
individu
transit
red
light
statu
selfidentif
qtc
reactor
dqtc
ms
greater
consider
given
discontinu
azithromycin
optim
electrolyt
statu
intensifi
countermeasur
place
telemetri
continu
rhythm
assess
ideal
follow
baselin
qtc
assess
therapi
may
initi
either
qtc
reassur
low
risk
vast
major
patient
vari
qtc
countermeasur
place
flag
increas
risk
time
ontherapi
qtc
surveil
dictat
pharmacokinet
therapi
use
also
practic
logist
institut
method
qtc
monitor
ecg
approach
qtc
surveil
deem
import
one
machin
design
acquisit
data
limit
number
ecg
technicianspersonnel
use
minim
ppe
util
personnel
exposur
also
number
ontherapi
qtc
assess
constrain
minim
personnel
exposur
risk
ppe
consumpt
scenario
place
red
light
statu
baselin
qtc
ms
greater
initi
ontherapi
qtc
obtain
around
hour
first
dose
hour
hour
follow
treatment
initi
patient
receiv
either
green
light
yellow
light
statu
probabl
forego
earli
qtc
assess
wait
hour
hour
ondrug
qtc
determin
ontherapi
qtc
ms
greater
patient
selfidentifi
qtc
reactor
dqtc
ms
greater
qtc
countermeasur
need
reexamin
medic
stop
effort
neutral
increas
potenti
ditdp
discd
figur
contrast
medic
center
abl
implement
fda
emergencyapprov
smartphoneen
approach
figur
determin
qtc
telemetri
strip
ecg
technician
exposur
risk
consumpt
ppe
individu
would
elimin
patient
qtc
could
obtain
health
care
team
alreadi
present
exampl
qtc
obtain
per
shift
anoth
vital
sign
increas
qtc
surveil
would
enabl
discoveri
qtc
reactor
implement
countermeasur
sooner
hope
would
therebi
circumv
potenti
prevent
tragedi
discd
figur
final
patient
wide
qr
complex
either
ventricular
pace
rightleft
bundl
branch
block
wide
qr
complex
qtc
adjust
need
made
otherwis
patient
receiv
red
light
signal
inappropri
result
therapi
delay
discontinu
avoid
altogeth
set
simplest
approach
maintain
previous
indic
qtc
green
yellow
red
light
threshold
appli
simpl
formula
account
wide
qr
complex
wide
qr
complexeadjust
qtc
qtc
e
qr
ms
exampl
patient
left
bundl
branch
block
yield
qr
complex
ms
qtc
ms
scenario
would
appear
activ
red
light
pathway
figur
howev
wide
qr
complexeadjust
qtc
would
ms
e
ms
ms
red
light
statu
rather
green
light
go
statu
much
qtc
reassur
patient
low
risk
discd
coronaviru
pandem
continu
spread
wreak
havoc
econom
loss
importantli
tragic
death
thousand
throughout
world
must
part
war
wash
hand
physic
distanc
core
compon
contain
effort
flatten
curv
develop
coronaviru
vaccin
progress
unpreced
speed
still
least
month
away
meantim
hope
longago
discov
antimalari
drug
hydroxychloroquin
may
lifesav
therapeut
efficaci
hope
simpl
qtc
surveil
strategi
enabl
innov
fda
emerg
approv
help
prevent
altogeth
least
substanti
reduc
number
druginduc
ventricular
arrhythmia
sudden
cardiac
death
particularli
widespread
adopt
util
medic
